.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XX12_Lefamulin.Lefamulin

Information

Lefamulin is a pleuromutilin class antibiotic indicated for the treatment of community-acquired bacterial pneumonia (CABP) in adults. It is approved and used clinically and possesses activity against a range of Gram-positive and atypical bacterial pathogens.

Pharmacokinetics

Pharmacokinetics in healthy adult subjects following intravenous administration.

References

1. Zhang, L, et al., & Rubino, CM (2019). Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods. The Journal of antimicrobial chemotherapy 74(Suppl 3) iii27–iii34. DOI:10.1093/jac/dkz088 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30949708

2. van Os, W, & Zeitlinger, M (2024). Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections. The Journal of antimicrobial chemotherapy 79(2) 443–446. DOI:10.1093/jac/dkad401 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38174805

3. Bian, X, et al., & Zhang, J (2024). Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia. Frontiers in pharmacology 15 1456741–None. DOI:10.3389/fphar.2024.1456741 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39525637

Revisions

• 06/2025 initial generated model